XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates

Group 1: Earnings Performance - XOMA Royalty reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.26 per share, and showing improvement from a loss of $0.86 per share a year ago, resulting in an earnings surprise of 123.08% [1] - The company posted revenues of $15.91 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 159.58%, compared to revenues of $1.49 million in the same quarter last year [2] Group 2: Stock Performance and Outlook - XOMA Royalty shares have declined approximately 5.7% since the beginning of the year, while the S&P 500 has seen a decline of -0.6% [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.18 on revenues of $7.38 million, and for the current fiscal year at -$0.50 on revenues of $29.75 million [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which XOMA Royalty belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8] - Another company in the same industry, Kamada, is expected to report quarterly earnings of $0.07 per share, reflecting a year-over-year increase of 75%, with revenues projected at $41.81 million, up 10.8% from the previous year [9]